Table 1 Clinico-pathological data of the entire patient cohort.
From: Integrin beta1 (ITGB1) as a prognostic marker in esophageal adenocarcinoma
Total | Integrin beta1 expression | P value | |||||
|---|---|---|---|---|---|---|---|
Negative | Positive | ||||||
N | % | N | % | N | % | ||
640 | 100 | 513 | 80.2 | 127 | 19.8 | ||
Sex | |||||||
Female | 76 | 11.9 | 59 | 77.6 | 17 | 22.4 | 0.542 |
Male | 564 | 88.1 | 454 | 80.5 | 110 | 19.5 | |
Age group | |||||||
< 65 years | 327 | 53.0 | 264 | 80.7 | 63 | 19.3 | 0.762 |
> 65 years | 290 | 47.0 | 231 | 79.7 | 59 | 20.3 | |
Neoadjvuant therapy | |||||||
No | 265 | 41.4 | 213 | 80.4 | 52 | 19.6 | 0.494 |
Yes | 375 | 58.6 | 300 | 80.0 | 75 | 20.0 | |
Tumor stage | |||||||
(y) pT1 | 133 | 20.9 | 112 | 84.2 | 21 | 15.8 | 0.103 |
(y) pT2 | 123 | 19.4 | 105 | 85.4 | 18 | 14.6 | |
(y) pT3 | 359 | 56.5 | 276 | 76.9 | 83 | 23.1 | |
(y) pT4 | 20 | 3.1 | 15 | 75.0 | 5 | 25.0 | |
Lymph node stage | |||||||
(y) pN0 | 259 | 40.6 | 222 | 85.7 | 37 | 14.3 | 0.039 |
(y) pN1 | 210 | 32.9 | 162 | 77.1 | 48 | 22.9 | |
(y) pN2 | 88 | 13.8 | 67 | 76.1 | 21 | 23.9 | |
(y) pN3 | 81 | 12.7 | 61 | 75.3 | 20 | 24.7 | |
UICC stage | |||||||
I | 101 | 15.9 | 86 | 85.1 | 15 | 14.9 | 0.208 |
II | 80 | 12.6 | 67 | 83.8 | 13 | 16.3 | |
III | 287 | 45.2 | 229 | 79.8 | 58 | 20.2 | |
IV | 167 | 26.3 | 126 | 75.4 | 41 | 24.6 | |
Kras mutation | |||||||
No | 415 | 82.0 | 352 | 84.8 | 63 | 15.2 | 0.044 |
Yes | 91 | 18.0 | 69 | 75.8 | 22 | 24.3 | |
